Question 1

What is trastuzumab deruxtecan?

Accepted Answer

Trastuzumab deruxtecan is a targeted therapy known as an antibody-drug conjugate. It consists of a HER2-directed monoclonal antibody linked to a topoisomerase I inhibitor, which is a type of chemotherapy. The antibody portion of the molecule identifies and attaches to specific receptors on the surface of cells.

Once the medication binds to these receptors, it is taken into the cell where the chemotherapy component is released. This mechanism allows for the targeted delivery of the medication to specific cells while minimizing exposure to cells that lack the target receptor.

Question 2

What is trastuzumab deruxtecan used for?

Accepted Answer

Trastuzumab deruxtecan is used to treat:

HER2-positive breast cancer

HER2-low breast cancer

HER2-positive gastric or gastroesophageal junction adenocarcinoma

and others.

Question 3

How does trastuzumab deruxtecan work?

Accepted Answer

Mechanism of Action

Trastuzumab deruxtecan belongs to a class of medications known as antibody-drug conjugates (ADCs). It is designed to deliver a potent chemotherapy drug directly to cancer cells while limiting exposure to healthy cells.

Targeting HER2 Proteins

The medication consists of two main parts linked together: a monoclonal antibody and a chemotherapy drug. The antibody part is designed to find and attach to human epidermal growth factor receptor 2 (HER2), a protein found on the surface of many types of cancer cells. The antibody acts as a homing device to locate these specific cells.

Internalization and Release

Once the medication attaches to the HER2 protein on a cancer cell, the entire complex is taken inside the cell. After it is inside, enzymes break the link between the antibody and the chemotherapy drug (deruxtecan), releasing the chemotherapy to do its work.

Cell Death and the Bystander Effect

The released chemotherapy works by blocking an enzyme called topoisomerase I, which cells need to repair and copy their DNA. When this enzyme is blocked, the cancer cell cannot multiply and eventually dies. Because the chemotherapy part of this medication can pass through cell membranes, it may also move into and kill neighboring cancer cells, a process sometimes called the bystander effect.

Question 4

What are the active ingredients in trastuzumab deruxtecan?

Accepted Answer

The active ingredient in trastuzumab deruxtecan is trastuzumab .

Question 5

What are the side effects of trastuzumab deruxtecan?

Accepted Answer

Common side effects of trastuzumab deruxtecan may include:

Nausea

Fatigue

Vomiting

and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is trastuzumab deruxtecan?

Accepted Answer

Trastuzumab deruxtecan belongs to the antibody-drug conjugate drug class.

Question 7

What is the dosage of trastuzumab deruxtecan and how do I take it?

Accepted Answer

Administration

Trastuzumab deruxtecan is given as an infusion into a vein (intravenously) by a healthcare provider in a medical setting, such as a hospital or clinic. It is not a medication you take at home.

Treatment Schedule

This medication is typically administered once every three weeks. Your healthcare provider will determine the exact schedule based on your specific condition and how you respond to the treatment.

Infusion Process

The first infusion is usually given slowly over a period of 90 minutes so your healthcare provider can monitor for any reactions. If the first infusion is well-tolerated, subsequent infusions may be given over a shorter period, such as 30 minutes.

Before each treatment, your doctor may give you medications to help prevent nausea and vomiting caused by the infusion.

Missed Doses

If you miss an appointment for your infusion, contact your healthcare provider immediately to reschedule. It is important to receive the medication as scheduled. Do not wait until your next planned treatment date to address a missed dose, and the time between doses should not be shortened.

Question 8

Is trastuzumab deruxtecan safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy Risks

Trastuzumab deruxtecan can cause fetal harm when administered to a pregnant woman. Based on its mechanism of action, exposure to this medication during pregnancy may lead to low levels of amniotic fluid. This condition can cause serious problems for the fetus, including underdeveloped lungs, skeletal abnormalities, and death.

Individuals who can become pregnant should have a pregnancy test to confirm they are not pregnant before starting treatment. It is important to discuss the potential risks to a fetus with a healthcare provider if pregnancy occurs or is planned during treatment.

Contraception Requirements

Females: Use effective contraception during treatment and for at least 7 months after the final dose.

Males: Those with female partners who can become pregnant should use effective contraception during treatment and for at least 4 months after the final dose.

Breastfeeding

It is not known if trastuzumab deruxtecan passes into human breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended during treatment and for 7 months after the last dose.

Question 9

What forms and strengths does trastuzumab deruxtecan come in?

Accepted Answer

Dosage Forms

Trastuzumab deruxtecan is supplied as a sterile, preservative-free powder in a single-dose vial. The powder is typically described as a white to yellowish-white cake.

Administration

This medication is intended for intravenous use only. Before administration, a healthcare provider must reconstitute the powder and further dilute it into an infusion bag. It is not available in oral forms, such as tablets or capsules, and cannot be self-administered.

Question 10

What is the FDA approval status of trastuzumab deruxtecan?

Accepted Answer

FDA Approval Status

Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several advanced or metastatic cancers. These approvals are generally based on the presence of the HER2 protein or specific HER2 mutations. Approved indications include:

Breast Cancer: Used for HER2-positive metastatic breast cancer, as well as HER2-low and HER2-ultralow metastatic breast cancer in patients who have received prior systemic treatments.

Gastric Cancer: Used for HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Lung Cancer: Used for metastatic non-small cell lung cancer (NSCLC) with specific HER2 mutations.

Solid Tumors: Used for adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior treatment and have no satisfactory alternative treatment options.

Boxed Warnings

The FDA-approved labeling for trastuzumab deruxtecan includes a Boxed Warning, the most serious type of warning, for the following risks:

Interstitial Lung Disease (ILD) and Pneumonitis: This medication can cause severe, life-threatening, or fatal lung inflammation. Patients must be monitored for new or worsening respiratory symptoms such as cough, fever, or shortness of breath.

Embryo-Fetal Toxicity: Exposure to this drug during pregnancy can cause harm to a developing fetus. Effective contraception is required for patients of reproductive potential during treatment and for a specified period after the final dose.

Regulatory History

Trastuzumab deruxtecan received its initial accelerated approval from the FDA in December 2019. Since then, its approved uses have expanded significantly to include a broader range of HER2-expressing tumors across different organs, based on clinical trial data demonstrating its efficacy in these populations.

Question 11

What should I know about trastuzumab deruxtecan and cost?

Accepted Answer

Factors Affecting Cost

Trastuzumab deruxtecan is a specialty medication that is supplied in 100 mg single-dose vials. Because the dosage is calculated based on a patient's body weight, the amount of medication needed—and the resulting cost—will vary from person to person. Additionally, since the drug must be administered as an intravenous infusion by a healthcare professional, total costs typically include both the price of the medication and facility fees for the clinical service.

Insurance and Prior Authorization

Most insurance plans cover trastuzumab deruxtecan for its FDA-approved uses, though many require prior authorization. This process involves your healthcare provider submitting documentation to your insurance company to prove the medical necessity of the treatment before they agree to cover the cost. Patients may still be responsible for out-of-pocket expenses, such as deductibles, co-pays, or co-insurance.

Financial Assistance Programs

Financial assistance may be available for patients who have difficulty affording their treatment. The manufacturer often provides patient support programs, which may include:

Co-pay assistance: For eligible patients with commercial insurance to help lower out-of-pocket costs.

Patient assistance programs: For patients who are uninsured or underinsured and meet specific financial criteria.

Support services: Resources to help patients and providers navigate insurance coverage and reimbursement processes.

It is recommended to speak with a hospital financial counselor or a specialty pharmacy to get a detailed estimate of costs based on your specific insurance plan and treatment schedule.

trastuzumab deruxtecan

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?